Financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with Simufilam in Alzheimer’s disease. Here are some of the key things you need to know about the coronavirus pandemic.
Source: streetinsider.comPublished on 2022-08-03
Related news
- Rare ocean climate data transmitted live from Seaexplorer – YC de Monaco during Vendée Globe Race
- An Overview Of Today Alzheimer Disease Development Field
- Provinces at odds with Ottawa over COVID - 19 vaccine distribution
- The Mekong Reports China Doesnt Want You to See
- Leveraging IoT For OOH
- RARE - X Launches Diversity , Equality , and Inclusion Program
- ClassLink and Canva for Education Partner to Deliver Creativity to Classrooms
- Airbus forecasts $4 . 6 trillion global market for aircraft services in next 20 years
- The City of Baltimore is launching an updated open data portal on December 31
- Asceneuron Awarded Second Grant from The Michael J . Fox Foundation for Accelerated Research into Novel Parkinson Disease Therapies
- Mental health support , not increased policing , needed during pandemic , study finds
- Delayed by COVID , CT redistricting ramps up | Hartford Business Journal
- 500 Promising Individuals Worldwide Receive Linux Foundation IT Training & Certification Scholarships
- RARE - X Study Delivers Insights for Diversity , Equality , and Inclusion Programs
- Four ways the finance sector can end financial exclusion in 2021